Table 2.
IC50 values of chemotherapy and targeted therapy drugs vs. C212 in quiescent (Q) and growing (G) leukemia cells (48-h treatment)
| Drugs | HL60 | K562 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IC50 | AUC | IC50 | AUC | |||||||||
| Q | G | Q/G | Q | G | Q/G | Q | G | Q/G | Q | G | Q/G | |
| Paclitaxel/nM | 62.2 | 10.8 | 5.76 | 148.2 | 103.8 | 1.43 | > 120 | 58.5 | > 2.05 | 191.8 | 162.7 | 1.18 |
| Topotecan/nM | 57.8 | 13.3 | 4.35 | 142.8 | 112.9 | 1.27 | > 2000 | 752.9 | > 2.66 | 182.9 | 173.4 | 1.06 |
| Doxorubicin/μM | 0.6 | 0.3 | 2.00 | 162.5 | 139.3 | 1.17 | 0.7 | 0.4 | 1.75 | 182.0 | 149.5 | 1.22 |
| Midostaurin/μM | 12.1 | 2.9 | 4.17 | 185.3 | 133.2 | 1.39 | 324.5 | 300.4 | 1.08 | |||
| C212/μM | 2.3 | 2.3 | 1.00 | 128.7 | 124.3 | 1.04 | 2.8 | 7.7 | 0.36 | 154.3 | 178.3 | 0.87 |